NCT04686591

Absolute Bioavailability and ADME Study of [14C]AZD9977 in Healthy Male Subjects

Name: Clinical Trial NCT04686591
Creator: AstraZeneca
Keywords: Cardiovascular Disease, AZD9977 capsule 50 mg, Phase 1, drug, clinical trial, United Kingdom

A Phase I, Open-label Study of Absolute Bioavailability and Absorption-Distribution-Metabolism-Excretion (ADME) of [14C]AZD9977 in Healthy Male Subjects

AstraZeneca·Phase 1·ClinicalTrials.gov·drugCompleted

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Cardiovascular Disease
Drug/Device/Intervention: AZD9977 capsule 50 mg
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: AstraZeneca
Location: Ruddington, United Kingdom

Timeline & enrollment

Phase: Phase 1
Start date: Dec 21, 2020
End date: Feb 04, 2021
Enrollment: 8 participants

Primary outcome

Absolute bioavailability of AZD9977,The cumulative amount of AZD9977 excreted (CumAe),The cumulative amount of AZD9977 excreted and expressed as a percentage of the administered dose (CumFe),Assessment of metabolites in plasma by liquid chromatography-radiochemical-detection and subsequent mass spectrometry,Assessment of metabolites in urine by liquid chromatography-radiochemical-detection and subsequent mass spectrometry,Assessment of metabolites in faeces by liquid chromatography-radiochemical-detection and subsequent mass spectrometry

Summary

Study to Assess the Absorption, Metabolism, and Excretion of [14C]AZD9977 after a Single-Dose Oral Administration

ICD-10 classifications

Cardiovascular disease, unspecifiedHypertensive heart diseaseHeart disease, unspecifiedAtherosclerotic cardiovascular disease, so describedAtherosclerotic heart disease

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT04686591
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT04686591 through Pure Global AI's free database. This Phase 1 trial is sponsored by AstraZeneca and is currently Completed. The study focuses on Cardiovascular Disease. Target enrollment is 8 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.